Videos

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.

Krina Patel, MD, MSc, presents the case of a 65-year-old woman with relapsed/refractory multiple myeloma, and the panel discusses the optimal sequencing of her treatment regimens.

Closing out his discussion on chronic graft-vs-host disease, Yi-Bin Chen, MD, looks to the future of GVHD treatment.

Yi-Bin-Chen, MD, discusses the effect of GVHD recurrence and multiple-organ involvement on treatment decisions.

A summary of the systemic treatment options available for steroid-refractory chronic GVHD.

A comprehensive overview of the various treatment options for chronic graft-vs-host disease.

Yi-Bin Chen, MD, describes acute and chronic GVHD, and details the typical symptoms and presentations.

Anna Jo Bodurtha Smith, MD, discusses background on her research regarding insurance-mediated disparities in gynecologic oncology.

With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.

Casey M. Cosgrove, MD, discusses research exploring precision medicine concepts for endometrial cancer treatment.

Casey M. Cosgrove, MD, discusses biomarker-guided treatment for endometrial cancer.

Dr Jason Porter introduces three recent retrospective observational studies on use of biomarker testing in mNSCLC, which identified racial and socioeconomic disparities in testing patterns.

Panelists continue their dialogue on common challenges and barriers to use of biomarker testing in NSCLC, and share potential strategies to optimize use of testing.

Lori Leslie, MD, discusses ongoing clinical trials that are exploring chimeric antigen receptor T-cell therapy for the treatment of B-cell malignancies.

An expert on graft-vs-host disease provides an overview of GVHD prophylaxis and conditioning regimens prior to transplant.

Yi-Bin Chen, MD, an expert clinician and researcher, reviews a case study of a patient with GVHD and offers his initial impressions.

Gene G. Finley, MD, discusses some of the treatment options that have been used in the small cell lung cancer space, including intensive chemotherapies and targeted agents.

Nicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.

Chandler Park, MD shares clinical insights regarding care for patients with renal cell carcinoma, touching on treatment selection and managing adverse effects.

Thoughtful discussion of ongoing clinical trials in the renal cell carcinoma landscape, with a particular focus on their eventual clinical implications.

Expert panelists open their discussion on ALK+ non–small cell lung cancer and reflect on the impact of CNS metastasis in this setting.

Chandler H. Park, MD, discusses the treatment landscape for advanced renal cell carcinoma and factors that influence treatment decisions.

Alexander Spira, MD, PhD, FACP, discusses the combination of amivantamab-vmjw and lazertinib for patients with relapsed or refractory EGFR-mutant non–small cell lung cancer and findings presented at the 2022 IASLC World Conference on Lung Cancer.

Drs Krina Patel and Hana Safah explain their impressions of the data on BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma and its potential impact on clinical practice.

Dr Sagar Lonial highlights efficacy and safety data from the KarMMA and CARTITUDE-1 clinical trials.

Lori Leslie, MD, describes the cohorts of the phase 2 ZUMA-2 study and discusses the potential impact of brexucabtagene autoleucel in the mantle cell lymphoma landscape.

Jashodeep Datta, MD, explains KRAS and TP53 co-alterations in patients with pancreatic cancer.

Dr Vail shares insight into his ideal institutional approach to biomarker testing for NSCLC, emphasizing the need for local molecular pathology expertise and available in-house biomarker panels.

Eric Vail, MD introduces a patient case, a 71-year-old Asian woman newly diagnosed with mNSCLC, followed by a focused discussion on how the panel would have approached biomarker testing and treatment initiation for the patient.